REPORT ATTRIBUTE |
DETAILS |
Historical Period |
2019-2022 |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Excessive Daytime Sleepiness Market Size 2024 |
USD 5355 million |
Excessive Daytime Sleepiness Market, CAGR |
9.2% |
Excessive Daytime Sleepiness Market Size 2032 |
USD 10827.8 million |
Market Overview:
The Excessive Daytime Sleepiness Market is projected to grow from USD 5355 million in 2024 to an estimated USD 10827.8 million by 2032, with a compound annual growth rate (CAGR) of 9.2% from 2024 to 2032.
The market’s key drivers include the increasing prevalence of sleep disorders globally, often linked to lifestyle changes, stress, and chronic conditions. Rising awareness campaigns by healthcare organizations and governments about the importance of sleep health have encouraged early diagnosis and treatment. Furthermore, advancements in treatment options, including wakefulness-promoting agents, central nervous system stimulants, and cognitive-behavioral therapies, are enhancing patient outcomes. The integration of digital health solutions, such as wearable devices and mobile apps, for real-time sleep monitoring and management is also driving market growth. Additionally, the growing geriatric population, which is more susceptible to sleep disorders, further amplifies the demand for effective EDS management solutions.
Regionally, North America holds the largest market share, driven by a well-established healthcare infrastructure, high awareness levels, and significant investments in sleep disorder research. The presence of leading pharmaceutical companies and increasing adoption of advanced therapies contribute to the region’s dominance. Europe follows closely, supported by strong healthcare policies and growing awareness about EDS-related risks. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth due to rising healthcare investments, a large undiagnosed patient pool, and increasing adoption of diagnostic technologies. Emerging markets in Latin America and the Middle East & Africa are also showing potential for growth, supported by improving healthcare infrastructure and rising awareness about sleep health.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Insights:
- The market is projected to grow from USD 5,355 million in 2024 to USD 10,827.8 million by 2032, with a CAGR of 9.2%, driven by rising sleep disorder prevalence and awareness campaigns.
- Technological advancements in diagnostics, such as wearable sleep trackers and polysomnography, are improving early detection and management outcomes for excessive daytime sleepiness.
- Increased adoption of advanced treatments, including wakefulness-promoting agents and cognitive-behavioral therapies, is enhancing patient care and broadening therapeutic options.
- The growing geriatric population, prone to sleep disorders, is amplifying demand for tailored treatment solutions in the global market.
- North America holds the largest market share, supported by advanced healthcare infrastructure, strong R&D investments, and high awareness levels.
- The Asia-Pacific region is the fastest-growing market, benefiting from healthcare investments, a large undiagnosed patient pool, and increasing medical tourism.
- Emerging markets in Latin America and the Middle East & Africa show potential due to improving healthcare infrastructure and rising awareness about sleep health solutions.
Market Drivers:
Rising Prevalence of Sleep Disorders
The increasing prevalence of sleep disorders such as narcolepsy, obstructive sleep apnea, and restless leg syndrome is a major driver of the excessive daytime sleepiness market. Changes in lifestyle, stress, and poor sleep hygiene have led to a rise in sleep-related health issues across all age groups. Sleep disorders often remain underdiagnosed, which prolongs the onset of effective treatment. For instance, Jazz Pharmaceuticals has developed innovative treatments such as solriamfetol, a wakefulness-promoting agent approved for managing excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. However, growing awareness among patients and healthcare providers is facilitating earlier diagnosis, thereby driving the demand for innovative therapies and solutions to manage EDS effectively.
Advances in Diagnostic and Treatment Technologies
Technological advancements in diagnostic tools and treatment modalities have significantly boosted the EDS market. Improved sleep monitoring devices, such as polysomnography and wearable sleep trackers, enable accurate and timely diagnosis, enhancing patient outcomes. For example, Inspire Medical Systems introduced its Upper Airway Stimulation (UAS) therapy, a neurostimulation device approved by the FDA for treating moderate-to-severe obstructive sleep apnea. Additionally, the development of advanced pharmacological treatments, including wakefulness-promoting agents and central nervous system stimulants, has expanded therapeutic options for managing excessive daytime sleepiness. Non-pharmacological approaches, such as cognitive-behavioral therapy for sleep, are also gaining traction, providing comprehensive solutions for patients.
Growing Awareness and Supportive Health Campaigns
Public awareness campaigns and initiatives led by healthcare organizations and governments are playing a pivotal role in addressing the burden of excessive daytime sleepiness. These efforts highlight the risks associated with untreated sleep disorders, such as cardiovascular issues, mental health challenges, and impaired productivity. Educational programs aimed at both patients and healthcare providers are fostering a better understanding of EDS, encouraging early intervention. For instance, the American Academy of Sleep Medicine launched the “More Than a Snore” campaign to raise awareness about obstructive sleep apnea. This initiative educates patients and healthcare providers on the risks of untreated sleep disorders and encourages early diagnosis and treatment. This growing awareness is not only increasing patient engagement but also motivating investments in research and development to create more effective treatment options.
Increasing Focus on Patient-Centric Care
The healthcare industry’s shift toward patient-centric care has greatly influenced the growth of the excessive daytime sleepiness market. Patients are increasingly seeking personalized treatment plans that address the root causes of their condition while minimizing side effects. Digital health tools, such as sleep tracking apps and telemedicine platforms, are empowering individuals to monitor and manage their symptoms in collaboration with healthcare professionals. For example, BetterNight has implemented a fully integrated telehealth solution for sleep apnea care. This approach combines home sleep testing, CPAP therapy management, and continuous patient monitoring to provide personalized and convenient care for individuals with sleep disorders. This emphasis on tailored care is driving innovation in the market, leading to the development of solutions that improve quality of life for those affected by EDS.
Market Trends:
Integration of Wearable Devices and Digital Health Solutions
The market is witnessing rapid adoption of wearable devices and digital health tools that revolutionize the monitoring and management of excessive daytime sleepiness. These technologies provide real-time insights into sleep patterns, enabling healthcare professionals to offer more precise diagnoses and personalized treatment plans. Artificial intelligence (AI) further enhances the analysis of sleep data, uncovering deeper insights into the causes of excessive daytime sleepiness. For instance, a study involving over 33,000 individuals and 5 million nights of sleep data demonstrated how wearable devices effectively track changes in sleep patterns, providing insights into health conditions such as insomnia or acute illnesses like COVID-19. The growing accessibility of these tools is driving their widespread use among patients and healthcare providers, fostering early intervention and improved management.
Expansion of Telemedicine for Sleep Disorder Management
Telemedicine is transforming the way excessive daytime sleepiness is treated by providing remote healthcare solutions. Patients can now consult specialists, receive follow-ups, and manage their sleep conditions without the need for in-person visits. This trend is particularly beneficial for individuals in remote or underserved areas and those with limited mobility. For example, a study on telemonitoring for obstructive sleep apnea (OSA) patients found that remote monitoring improved adherence to continuous positive airway pressure (CPAP) therapy, reducing delays in intervention by 18 days and increasing patient compliance rates to 78% compared to traditional care. The convenience and accessibility of telemedicine services are encouraging more people to seek treatment for excessive daytime sleepiness, supporting better health outcomes and driving market growth.
Innovations in Pharmaceutical Therapies
The pharmaceutical segment of the excessive daytime sleepiness market is experiencing significant advancements, with the development of new drugs and improved formulations. These innovations focus on enhancing efficacy while minimizing side effects, providing patients with safer and more effective options. Combination therapies, addressing multiple aspects of sleep disorders, are gaining attention for their comprehensive approach to symptom management. For instance, solriamfetol has demonstrated superior efficacy in reducing daytime sleepiness compared to other drugs like modafinil and sodium oxybate. The introduction of novel therapeutic pathways reflects the industry’s commitment to meeting evolving patient needs.
Emphasis on the Link Between Sleep Health and Chronic Conditions
Growing awareness of the connection between sleep disorders and chronic health issues, such as cardiovascular disease, mental health challenges, and workplace productivity loss, is reshaping market dynamics. For instance, studies by the American Heart Association have found that individuals with untreated sleep apnea are at a significantly higher risk of developing hypertension and other cardiovascular conditions. Research highlighting the consequences of untreated excessive daytime sleepiness has prompted employers and insurers to prioritize sleep health in wellness programs and coverage plans. This shift underscores the importance of addressing excessive daytime sleepiness for both individual and societal well-being, driving further investment in innovative solutions.
Market Challenges Analysis:
High Cost of Diagnostic and Treatment Solutions
The excessive daytime sleepiness market faces challenges associated with the high cost of diagnostic procedures and treatment options. Advanced diagnostic tools, such as polysomnography and wearable monitoring devices, are often expensive, limiting accessibility for patients in low- and middle-income regions. Similarly, newer pharmacological treatments with enhanced efficacy and safety profiles come with premium pricing, creating financial barriers for uninsured or underinsured patients. These cost-related challenges hinder widespread adoption and may delay timely diagnosis and treatment.
Limited Awareness and Underdiagnosis of Sleep Disorders
A significant restraint on the market is the widespread underdiagnosis of sleep disorders, including conditions that cause excessive daytime sleepiness. Many individuals remain unaware of the symptoms or health risks associated with untreated sleep disorders, leading to delayed intervention. Inadequate public awareness campaigns and insufficient training for primary care providers to recognize early symptoms further exacerbate this challenge. This lack of awareness results in a substantial portion of the affected population remaining untreated, limiting the market’s potential growth.
Regulatory and Reimbursement Barriers
Stringent regulatory requirements for the approval of new diagnostic tools and treatments pose a significant challenge for market players. These processes can be time-consuming and costly, delaying the introduction of innovative solutions. Additionally, inconsistent reimbursement policies across regions for sleep-related diagnostics and therapies create financial uncertainties for patients and healthcare providers. In regions with limited reimbursement coverage, the out-of-pocket costs deter patients from seeking necessary care.
Shortage of Trained Sleep Specialists
The effective diagnosis and management of excessive daytime sleepiness often require specialized expertise, which is lacking in many regions. A shortage of trained sleep specialists and facilities equipped to handle advanced sleep diagnostics limits access to quality care. This shortage is particularly pronounced in rural and underserved areas, where the infrastructure and professional expertise needed to manage sleep disorders are insufficient. Addressing these workforce gaps is essential for expanding access to effective treatment options.
Market Opportunities:
The excessive daytime sleepiness market presents significant growth opportunities driven by the increasing global prevalence of sleep disorders and heightened awareness of their impact on overall health. The demand for innovative diagnostic tools and advanced treatment solutions is rising as healthcare providers and patients prioritize early and accurate diagnosis. Technological advancements, such as AI-enabled sleep monitoring devices and wearable technologies, offer opportunities for real-time data collection and personalized care, enhancing patient outcomes. Additionally, the integration of telemedicine into sleep disorder management allows for greater accessibility and convenience, especially in remote and underserved areas, further expanding the market’s reach.
Emerging markets in regions such as Asia-Pacific, Latin America, and the Middle East & Africa present immense growth potential due to improving healthcare infrastructure and growing awareness about sleep health. Governments and private entities in these regions are investing heavily in healthcare advancements, creating favorable conditions for market expansion. The growing middle-class population, rising disposable incomes, and increasing medical tourism for cost-effective treatment options also contribute to the untapped opportunities in these areas. Furthermore, the shift towards patient-centric care, coupled with supportive policies promoting innovation in sleep health technologies and pharmaceuticals, underscores the potential for sustained market growth. Companies that can leverage these opportunities through strategic partnerships, localized product offerings, and tailored awareness campaigns are well-positioned to thrive in this evolving market landscape.
Market Segmentation Analysis:
The excessive daytime sleepiness market is segmented based on diseases, treatment types, distribution channels, end users, and regions, reflecting a comprehensive market landscape.
By Diseases, the market is dominated by conditions such as obstructive sleep apnea (OSA) and narcolepsy, with OSA accounting for a significant share due to its high prevalence globally. Narcolepsy represents a growing segment, driven by increasing awareness and advancements in diagnostic accuracy.
By Treatment, the market is divided into devices and therapeutic drugs. Devices, including diagnostic tools like polysomnography and therapeutic solutions like CPAP machines, hold a robust share due to their essential role in managing OSA. Therapeutic drugs, such as stimulants, antidepressants, amphetamine salts, and sodium oxybate, are witnessing increased adoption, particularly for narcolepsy management, supported by ongoing drug innovations.
By Distribution Channels, the market includes hospitals & sleep laboratories and home care settings. Hospitals and sleep laboratories lead the segment, given their advanced diagnostic capabilities. However, the home care segment is rapidly expanding due to the convenience of wearable diagnostic devices and portable therapy solutions.
By End User, hospitals and sleep clinics dominate the segment, driven by the availability of specialized facilities. Ambulatory surgical centers and home care settings are growing segments, catering to patients seeking cost-effective and accessible solutions.
Segmentation:
By Diseases:
- Obstructive Sleep Apnea (OSA)
- Narcolepsy
By Treatment:
- Devices (Diagnostics, Therapy)
- Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)
By Distribution channels:
- Hospitals & Sleep Laboratories
- Home Care Settings
By End User
- Hospitals
- Sleep Clinics
- Ambulatory Surgical Centers
- Home Care Settings
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America
North America dominates the excessive daytime sleepiness (EDS) market, accounting for approximately 35% of the global market share in 2024. The region’s leadership is driven by a well-established healthcare infrastructure, high awareness of sleep disorders, and significant investments in advanced diagnostic and therapeutic solutions. The United States, in particular, leads the market due to a strong focus on sleep health, widespread adoption of wearable sleep monitoring devices, and the presence of major pharmaceutical and medical device companies. The rising prevalence of obstructive sleep apnea and narcolepsy, coupled with growing awareness campaigns by healthcare organizations, further bolster the market in North America.
Europe
Europe holds the second-largest market share, contributing approximately 25% of the global market in 2024. The region benefits from a mature healthcare system, supportive reimbursement policies, and increased adoption of innovative technologies. Countries like Germany, the UK, and France are at the forefront, driven by strong government initiatives promoting early diagnosis and treatment of sleep disorders. The rising prevalence of lifestyle-related conditions, such as obesity and stress-induced insomnia, fuels demand for advanced EDS management solutions. Europe’s focus on integrating digital health technologies, including telemedicine and wearable devices, also supports market growth.
Asia-Pacific
Asia-Pacific is the fastest-growing region in the EDS market, expected to account for 20% of the global share by 2032. The rapid industrialization and urbanization in countries like China, India, and Japan are driving an increase in sleep-related disorders due to sedentary lifestyles and heightened stress levels. Governments in these countries are investing heavily in healthcare infrastructure and public awareness campaigns about sleep health, boosting demand for diagnostic and therapeutic solutions. Additionally, the growing popularity of medical tourism, supported by cost-effective treatments and skilled professionals, contributes to the region’s rapid growth.
Latin America and the Middle East & Africa
Latin America and the Middle East & Africa collectively contribute around 15% of the global market share. These regions are emerging markets, characterized by improving healthcare access, growing awareness about sleep disorders, and increasing disposable incomes. Countries such as Brazil, South Africa, and the UAE are witnessing gradual adoption of advanced sleep diagnostics and therapies. However, challenges such as limited infrastructure and a shortage of trained sleep specialists may restrain growth in certain areas.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key Player Analysis:
- Avadel Pharmaceuticals
- Becton, Dickinson and Company (BD)
- BIOPROJET
- BMC Medical Co. Ltd.
- Braebon Medical Corporation
- Cadwell Laboratories Inc. Ltd
- Compumedics
- Eisai Co., Ltd.
- Fisher & Paykel Healthcare
- GE Healthcare
- GlaxoSmithKline plc
- Hikma Pharmaceuticals
- Jazz Pharmaceuticals
- Koninklijke Philips N.V.
- ResMed Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
Competitive Analysis:
The excessive daytime sleepiness market is characterized by intense competition, with key players focusing on innovation, strategic collaborations, and geographic expansion to maintain their market position. Leading pharmaceutical companies such as Jazz Pharmaceuticals, Takeda Pharmaceuticals, and Teva Pharmaceuticals dominate the market with their established product portfolios for managing narcolepsy and sleep apnea. These firms invest heavily in research and development to introduce novel therapeutics with enhanced efficacy and safety profiles. For instance, Jazz Pharmaceuticals’ Xyrem® (sodium oxybate) is a well-known treatment for narcolepsy with cataplexy, providing significant relief for patients. Medical device manufacturers, including ResMed, Philips, and Fisher & Paykel Healthcare, play a crucial role in providing advanced diagnostic tools and therapeutic devices such as CPAP machines and wearable monitors. Emerging companies are leveraging digital health technologies to offer AI-enabled solutions for sleep monitoring and personalized treatment. The competitive landscape is further shaped by increasing mergers, acquisitions, and partnerships aimed at expanding product offerings and addressing unmet needs, particularly in high-growth regions such as Asia-Pacific.
Recent Developments:
- In October 2024, ResMed unveiled its first fabric CPAP mask, the AirTouch N30i, designed for greater comfort and ease of use in treating sleep apnea. This launch aligns with ResMed’s broader strategy to innovate in sleep health technologies as part of its recently announced 2030 Strategy.
- In October 2024, Takeda initiated a Phase 3 trial for TAK-861, a treatment for narcolepsy type 1. This late-stage development underscores Takeda’s commitment to advancing therapies for sleep disorders and its focus on delivering life-transforming treatments.
- In October 2024, Teva launched the first generic version of Sandostatin® LAR Depot (octreotide acetate) in the U.S., expanding access to treatments for conditions like acromegaly and severe diarrhea associated with carcinoid syndrome. While not directly targeting excessive daytime sleepiness, this launch reflects Teva’s focus on innovative and accessible therapies.
Market Concentration & Characteristics:
The excessive daytime sleepiness (EDS) market exhibits a moderately fragmented landscape, with a mix of established pharmaceutical companies, medical device manufacturers, and emerging players contributing to its growth. Key players such as Jazz Pharmaceuticals, Takeda Pharmaceuticals, ResMed, and Philips hold significant market shares, driven by their extensive product portfolios and global reach. These companies focus on continuous innovation, leveraging advancements in technology to enhance the efficacy of diagnostic tools and therapeutics. The market is characterized by rapid adoption of digital health solutions, including AI-enabled sleep monitors and telemedicine platforms, which cater to the rising demand for personalized care. Increasing investments in research and development by both established firms and startups are accelerating the introduction of novel treatments. Additionally, the growing emphasis on patient-centric solutions and regional expansions underscores the competitive yet collaborative nature of the market, fostering opportunities for sustained growth across various regions.
Report Coverage:
The research report offers an in-depth analysis based on By Diseases, By Treatment, By Distribution channels and By End UseIt details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Increasing prevalence of sleep disorders, such as obstructive sleep apnea and narcolepsy, will drive market expansion globally.
- Advancements in AI and wearable technology will enhance diagnostic accuracy and promote early intervention.
- The rise of telemedicine platforms will improve access to sleep disorder treatments, particularly in remote areas.
- Ongoing innovation in pharmacological treatments will lead to safer, more effective therapies with fewer side effects.
- Emerging markets in Asia-Pacific and Latin America will experience significant growth due to improving healthcare infrastructure and awareness.
- Adoption of personalized healthcare solutions will cater to diverse patient needs, boosting demand for tailored treatment plans.
- Growing public awareness of the health risks associated with untreated sleep disorders will encourage early diagnosis and intervention.
- Integration of digital health solutions with conventional care models will streamline patient management and improve outcomes.
- Expanding medical tourism in cost-effective regions will attract international patients, fostering market growth.
- Collaborative efforts among stakeholders, including government initiatives, will support research, innovation, and adoption of advanced sleep management solutions.